Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ARIAD Pharmaceuticals, an oncology company, has begun Phase 3 randomized trial of ponatinib, an investigational pan-BCR-ABL inhibitor that also selectively inhibits certain other tyrosine kinases in preclinical studies, including FLT3, RET, KIT, FGF and PDGF receptors.
Subscribe to our email newsletter
Evaluation of Ponatinib versus Imatinib in Chronic Myeloid Leukemia (EPIC) trial of ponatinib will be conducted in newly diagnosed patients with chronic myeloid leukemia (CML).
The trial will evaluate the efficacy of ponatinib in comparison to imatinib based on evaluation of the primary endpoint of major molecular response (MMR) rate at 12 months.
ARIAD chairman and chief executive officer Harvey Berger said the treatment of newly diagnosed CML patients has shifted in recent years to the use of second-generation BCR-ABL inhibitors.
"The EPIC trial will evaluate whether ponatinib – a pan-BCR-ABL inhibitor – produces anti-leukemic responses in these newly diagnosed patients and potentially prevents the emergence of resistance mutations seen with other tyrosine kinase inhibitors," Berger added.
Approximately 500 patients will be randomized 1:1 to standard doses of ponatinib (45mg given orally once daily) or imatinib (400mg given orally once daily).
Escalation of the imatinib dose to 600mg or 800mg per day is permitted and ARIAD anticipates completing enrolment in the trial by the end of 2013.
The primary endpoint of the trial is the MMR rate at 12 months of treatment while the key secondary endpoints include MMR at five years, MR at three months (a reduction in the level of BCR-ABL transcripts to 10% or less), complete cytogenetic response rate at 12 months, progression-free survival and overall survival.